“…A report on 1,209 bone biopsies from five different countries (Brazil, Uruguay, Argentina, Portugal, and Spain) showed that low turnover osteomalacia and mixed uraemic osteodystrophy were more common in Brazil, Uruguay, and Argentina while hyperparathyroid bone disease predominated the picture in Portugal and Spain. 15 In the series reported by Onyemekehia 9 , osteitis fibrosa cystica was the commonest histological lesion found on bone biopsies.…”
“…A report on 1,209 bone biopsies from five different countries (Brazil, Uruguay, Argentina, Portugal, and Spain) showed that low turnover osteomalacia and mixed uraemic osteodystrophy were more common in Brazil, Uruguay, and Argentina while hyperparathyroid bone disease predominated the picture in Portugal and Spain. 15 In the series reported by Onyemekehia 9 , osteitis fibrosa cystica was the commonest histological lesion found on bone biopsies.…”
“…The available information regarding RO has mainly been derived from a series of observational studies showing a trend in the prevalence of high turnover disease, a decrease in osteomalacia, and stabilization of adynamic bone disease over the last decades [11][12][13][14][15] . A recent study observed a modification in the proportion of RO distribution, suggesting that low bone turnover disease can occur frequently during the late stages of CKD 16 .…”
ABSTRACT Introduction: Mineral and bone disorders (MBD) are major complications of chronic kidney disease (CKD)-related adverse outcomes. The Brazilian Registry of Bone Biopsy (REBRABO) is an electronic database that includes renal osteodystrophy (RO) data. We aimed to describe the epidemiological profile of RO in a sample of CKD-MBD Brazilian patients and understand its relationship with outcomes. Methods: Between August 2015 and March 2018, 260 CKD-MBD stage 3-5D patients who underwent bone biopsy were followed for 12 to 30 months. Clinical-demographic, laboratory, and histological data were analyzed. Bone fractures, hospitalizations, and death were considered the primary outcomes. Results: Osteitis fibrosa, mixed uremic osteodystrophy, adynamic bone disease, osteomalacia, osteoporosis, and aluminum (Al) accumulation were detected in 85, 43, 27, 10, 77, and 65 patients, respectively. The logistic regression showed that dialysis vintage was an independent predictor of osteoporosis (OR: 1.005; CI: 1.001-1.010; p = 0.01). The multivariate logistic regression revealed that hemodialysis treatment (OR: 11.24; CI: 1.227-100; p = 0.03), previous parathyroidectomy (OR: 4.97; CI: 1.422-17.241; p = 0.01), and female gender (OR: 2.88; CI: 1.080-7.679; p = 0.03) were independent predictors of Al accumulation; 115 patients were followed for 21 ± 5 months. There were 56 hospitalizations, 14 deaths, and 7 fractures during follow-up. The COX regression revealed that none of the variable related to the RO/turnover, mineralization and volume (TMV) classification was an independent predictor of the outcomes. Conclusion: Hospitalization or death was not influenced by the type of RO, Al accumulation, or TMV classification. An elevated prevalence of osteoporosis and Al accumulation was detected.
“…The toxicity of aluminium (Al) in animals and in humans and its role to potentiate damage to brain [1,2], bone and bone marrow cells [3,4], in particular in patients with chronic kidney disease (CKD) on the Alcontaining phosphate binders [5], is well established although the mechanism is unclear. Altmann et al [6] have also confirmed that a considerable damage to the cerebral function has occurred in people who were exposed to water accidentally contaminated with Al sulphate in the Camelford area of Cornwall in England in 1988 [6].…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.